News

miRagen and Archemix will collaborate on conjugated aptamer-microRNA therapies. miRagen and Archemix to jointly pursue R&D efforts and contribute resources under the agreement. It includes an exclusive option

Regeneron has reported the enrollment of the first patient in the phase 3 program of VEGF Trap-Eye, for the treatment of central retinal vein occlusion (CRVO). Regeneron has

EnteroMedics has reported a net loss of $10.4 million, or $0.34 per share, for the three months ended June 2009. For the six months ended June 2009, the

The company’s net income and diluted earnings per share for the 2009 second quarter were $1.27 billion and $0.94 respectively, as compared to $1.12 billion and $0.83 respectively,

China Aoxing has received renewal of the Good Manufacturing Practice (GMP) certification for its capsule formulation and packaging production facility. Reportedly, the certificate of compliance has a five-year

Bristol-Myers Squibb has reported net sales of $5.34 billion for the second quarter of 2009, as compared to $5.2 billion during the previous year. This represented an increase

Galapagos has received a milestone payment of E2.5 million in its osteoporosis collaboration with Eli Lilly.   Reportedly, in December 2007, Lilly and Galapagos initiated an alliance to

Rigel has reported that in the TASKi3 phase 2b clinical trial in rheumatoid arthritis (RA) study, has failed to meet its efficacy endpoints. Reportedly, the patients who had

Arno Therapeutics has initiated dosing of the first patient in a phase II clinical study of AR-67 in adult patients with myelodysplastic syndrome (MDS), who have failed prior